Subbu Nambi Analyst Performance

Managing Director & Equity Research Analyst at Guggenheim

Subbu Nambi is a stock analyst at Guggenheim focused in the medical sector, covering 13 publicly traded companies. Over the past year, Subbu Nambi has issued 19 stock ratings, including buy and hold recommendations. While full access to Subbu Nambi's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Subbu Nambi's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 19 Last 0 Years
Buy Recommendations: 89.47% 17 Buy Ratings
Companies Covered: 13 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	89.5%	17 ratings
Hold	10.5%	2 ratings
Sell	0.0%	0 ratings

Out of 19 total stock ratings issued by Subbu Nambi at Guggenheim, the majority (89.5%) have been Buy recommendations, followed by 10.5% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	76.9% of companies on NASDAQ	10 companies
NYSE	23.1% of companies on NYSE	3 companies

Subbu Nambi, an analyst at Guggenheim, currently covers 13 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 12 companies	92.3%
	Transportation 1 company	7.7%

Subbu Nambi of Guggenheim specializes in stock coverage within the Medical sector, with additional focus on Transportation companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 7 companies	53.8%
MEDICAL SERVICES 3 companies	23.1%
MEDICAL INFO SYS 1 company	7.7%
EQUIPMENT RENTAL & LEASING 1 company	7.7%
MED PRODUCTS 1 company	7.7%

About Subbu Nambi

Dr. Nambi is a Managing Director and Equity Research Analyst covering the Diagnostics & Life Sciences Tools sector. Before joining Guggenheim, she was a Research Director at General Atlantic, a private equity firm, where she focused on both public and private investment in the firm’s Life Sciences sector. Prior to that, Dr. Nambi was a Vice President on the Life Science Tools and Diagnostics team at Cowen. She also covered the Biotechnology sector at Cowen, where her focus was SMID cap biotech companies. Dr. Nambi holds a Ph.D. from the Indian Institute of Science.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
RVTY Revvity	10/15/2025	Initiated Coverage	$92.12		Neutral
ADPT Adaptive Biotechnologies	9/30/2025	Initiated Coverage	$13.46	$20.00	Buy
TEM Tempus AI	9/26/2025	Boost Price Target	$77.33	$95.00	Buy
GH Guardant Health	9/25/2025	Boost Price Target	$57.67	$67.00	Buy
CAI CAI International	8/13/2025	Boost Price Target	$32.46	$36.00	Buy
DHR Danaher	7/23/2025	Reiterated Rating	$190.04	$250.00	Buy
CAI CAI International	7/14/2025	Initiated Coverage	$26.51	$32.00	Buy
TEM Tempus AI	6/30/2025	Boost Price Target	$66.52	$75.00	Buy
NEOG Neogen	6/30/2025	Lower Price Target	$4.73	$10.00	Buy
ILMN Illumina	5/9/2025	Lower Price Target	$76.94	$114.00	Buy
TWST Twist Bioscience	5/6/2025	Reiterated Rating	$35.21	$50.00	Buy
EXAS Exact Sciences	4/11/2025	Reiterated Rating	$42.57	$60.00	Buy
MYGN Myriad Genetics	4/9/2025	Downgrade	$7.73		Neutral
EXAS Exact Sciences	3/28/2025	Set Price Target	$44.99	$60.00	Buy
CSTL Castle Biosciences	3/28/2025	Set Price Target	$20.10	$30.00	Buy
GH Guardant Health	2/24/2025	Reiterated Rating	$43.12	$56.00	Buy
ILMN Illumina	2/7/2025	Lower Price Target	$112.55	$150.00	Buy
GH Guardant Health	1/22/2025	Reiterated Rating	$48.30		Buy
NTRA Natera	1/17/2025	Boost Price Target	$168.50	$200.00	Buy

Stock Forecasts and Research Tools

Today's Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.